MRVI

Maravai LifeSciences Holdings, Inc. Healthcare - Biotechnology Investor Relations →

YES
69.7% BELOW
↓ Approaching Was -68.1% last week
-15% -10% -5% 0% 5% 10% 15%+
Buy Threshold $10.35
14-Week RSI 50

Maravai LifeSciences Holdings, Inc. (MRVI) closed at $3.14 as of 2026-02-02, trading 69.7% below its 200-week moving average of $10.35. This places MRVI in the extreme value zone. The stock is currently moving closer to the line, down from -68.1% last week. The 14-week RSI sits at 50, indicating neutral momentum.

Over the past 224 weeks of data, MRVI has crossed below its 200-week moving average 3 times. On average, these episodes lasted 71 weeks. The average one-year return after crossing below was -58.2%, suggesting these dips have not historically been reliable buying opportunities for this stock.

With a market cap of $1150 million, MRVI is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -40.9%. The stock trades at 1.9x book value.

Share count has increased 8.0% over three years, indicating dilution.

Over the past 4.4 years, a hypothetical investment of $100 in MRVI would have grown to $7, compared to $160 for the S&P 500. MRVI has returned -44.5% annualized vs 11.2% for the index, underperforming the broader market over this period.

In the past 12 months, corporate insiders have made 3 open-market purchases totaling $1,880,243. Multiple insiders purchased within a 30-day window — a cluster buy pattern that historically signals management confidence in the company's prospects. Notably, these purchases occurred while MRVI is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.

Free cash flow has been declining at a -100% compound annual rate. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.

Growth of $100: MRVI vs S&P 500

Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.

What Happens After MRVI Crosses Below the Line?

Across 3 historical episodes, buying MRVI when it crossed below its 200-week moving average produced an average return of -59.0% after 12 months (median -60.0%), compared to -8.3% for the S&P 500 over the same periods. After 24 months, the average return was -81.3% vs +11.0% for the index.

Each line shows $100 invested at the moment MRVI crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.

Advertisement

Insider Buying Activity

1 conviction buy in the past 12 months (purchases over $500K with meaningful position increases). 🔥 Cluster Buy Detected

DateInsiderTitleValueSharesPosition +%
2025-11-12BRUST BERNDChief Executive Officer$809,010250,559+11.3%

Historical Touches

MRVI has crossed below its 200-week MA 3 times with an average 1-year return of +-58.2% after recovery.

Crossed BelowRecoveredWeeksMax Depth1-Year ReturnReturn Since Touch
Nov 2021Nov 202139.7%-55.7%-91.0%
Jan 2022Feb 2022836.5%-60.6%-90.6%
Mar 2022Ongoing203+90.3%Ongoing-91.4%
Average71+-58.2%

Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.

Data as of Friday close, 2026-02-02